Andrew Saunders (CMO), Øystein Rekdal (CSO), Baldur Sveinbjørnsson (Senior researcher), Ketil Camilio (Senior researcher) and Brynjar Mauseth (PhD Student) represented Lytix Biopharma at the American Association for Cancer Research (AACR) in New Orleans April 16-21, 2016. Leading scientists and a large number of pharmaceutical companies attends the conference, and the mission is to prevent and cure cancer through research, education, communication and collaboration.

Together with scientific collaborators at Institut Gustav Roussy, Oslo University Hospital and University of Tromsø Lytix Biopharma presented 4 posters at the conference:

Sunday April 17, 2016:

• Enhanced antitumor activity achieved by combining the oncolytic peptide LTX-315 with anti-PD-L1 antibody

Monday April 18, 2016:

• LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain-dependent manner
• The amphiphatic ß(2,2)-amino acid LTX-401 induces complete regression of experimental hepatocellular carcinoma

Wednesday April 20, 2016:

• The oncolytic peptide LTX-315 enhances tumor-specific immune responses and tumor regression in murine 4T1 breast cancer when combined with doxorubicin

Andrew Saunders, Ketil Camilio and Øystein Rekdal.


Brynjar Mauseth and Baldur Sveinbjørnsson